Pradama will initially concentrate on the development of its lead product candidate for the prevention and/or treatment of osteoporosis – an orally available small molecule able to induce bone formation.

Pradama also has a unique bone-targeting technology which will allow specific delivery of compounds to bone.

For more information, please contact: